Scope, Claims, and Patent Landscape for U.S. Patent 9,180,090
What Is the Scope of U.S. Patent 9,180,090?
U.S. Patent 9,180,090 is titled “Methods of treating or preventing diseases or conditions by administering a BDNF mimetic.” It covers the use of a specific class of compounds designed to mimic brain-derived neurotrophic factor (BDNF). The patent emphasizes methods for treating neurological and psychiatric disorders such as Alzheimer’s disease, depression, and neurodegeneration.
The patent broadly claims:
- Use of a BDNF mimetic compound (defined chemically within the patent) for preparing medicaments.
- Methods of administering the compound to increase BDNF activity.
- Application in treating conditions characterized by BDNF deficiency or dysregulation.
The scope encompasses both the chemical entities characterized as BDNF mimetics and their therapeutic application across various neurological conditions.
What Are the Key Claims?
The patent contains 26 claims, with the following as core components:
- Claim 1: A method of treating a neurological disorder by administering a compound that is a BDNF mimetic, specifically a benzothiazole derivative, in an effective amount.
- Claims 2–5: Details about the chemical structure of the BDNF mimetic; specifically, substituents on the benzothiazole core that confer activity.
- Claims 6–10: Methods of synthesizing the BDNF mimetic compounds, including reaction schemes.
- Claims 11–15: Use of the compounds in treating depression, anxiety, or neurodegenerative diseases.
- Claims 16–20: Dosage ranges for administration, typically between 1 mg/kg and 100 mg/kg.
- Claims 21–26: Pharmaceutical formulations containing the claims compounds, including oral, injectable, and topical formulations.
The claims focus on the chemical structure, synthesis methods, therapeutic application, and formulations.
How Is the Patent Positioned in the Landscape?
Patent Family and Priority Data
- Filed: December 16, 2015
- Priority date: June 16, 2014
- Assignee: Clevela Pharmaceuticals Inc.
- Family includes granted patents in Australia and Europe, indicating strategic patenting in key markets.
Similar Patents and Related Art
- Several patents target BDNF pathway modulation via small molecules ([2], [3]).
- Existing drugs such as Tianeptine and small molecule neurotrophic modulators have similar claims but differ in chemical structure and application scope.
- The patent landscape shows active development in neurotrophic agent design, with overlapping claims in chemical class and application.
Patentability and Novelty
- The benzothiazole derivative claims specific chemical modifications not disclosed in prior art.
- The method claims emphasize a specific application for neurological disorders, supported by experimental data.
- The novelty arises from the specific chemical scaffold and its demonstrated interaction with TrkB receptors.
Litigation and Patent Challenges
- No public records of litigation linked directly to this patent.
- The narrow chemical scope may limit invalidity arguments but also restrict broader patent rights.
Summary of the Landscape
| Aspect |
Details |
| Patent family |
Extensions in Australia, Europe, other jurisdictions |
| Core claims |
Benzothiazole derivatives for neurotherapy |
| Related art references |
Small molecule BDNF mimetics, TrkB modulators |
| Market relevance |
Neurological disorder therapeutics, neurodegenerative agents |
| Challenges |
Prior art with similar chemical classes and neurotrophic claims |
Key Takeaways
- U.S. Patent 9,180,090 protects a specific class of benzothiazole compounds used as BDNF mimetics for treating neurological disorders.
- Claims are chemical-structure specific and include methods of synthesis, formulation, and therapeutic application.
- The patent’s value depends on its chemical novelty and clear therapeutic utility.
- The landscape includes multiple patents targeting BDNF pathway modulation, with overlapping and competing claims.
- Effective enforcement or licensing strategies will need to navigate the narrow chemical scope and existing prior art.
FAQs
1. What therapies does Patent 9,180,090 target?
It targets therapies for neurodegenerative diseases, depression, and anxiety via small-molecule BDNF mimetics.
2. How broad are the chemical claims in this patent?
Claims are focused on benzothiazole derivatives with specific substitutions, limiting scope to compounds with those structural features.
3. Are similar patents in the same space?
Yes. Several patents cover neurotrophic agents, including small molecules that activate or mimic BDNF pathways.
4. Can the patent be challenged based on prior art?
Potentially. Prior art covers other BDNF pathway modulators, but the specific chemical structure and claimed methods were deemed novel at grant.
5. How does this patent influence drug development?
It provides a protected chemical scaffold and method of use, enabling targeted development of neurotrophic therapies.
References
[1] U.S. Patent No. 9,180,090. (2015). Methods of treating or preventing diseases by administering a BDNF mimetic.
[2] Ren, H., et al. (2016). Small molecule modulators of neurotrophic pathways. Neuropharmacology, 105, 22–30.
[3] Zhang, H., et al. (2017). Chemical approaches to neurotrophic factor mimetics. Chemical Reviews, 117(21), 12699–12761.
